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Background: This study investigated the frequency of patients with HCC who refused cancer-directed surgery and the
characteristics and outcomes of these patients. Patients and Methods: A retrospective study was performed using data from the
Surveillance, Epidemiology, and End Results (SEER) Program. Characteristics of patients who refused CDS were compared with
those who accepted surgery using logistic regression. The eﬀect of refusing CDS on mortality was evaluated by Cox proportional
hazards analysis. Results: Among 4373 surgical candidates, 142 patients (3.2%) refused the recommended CDS. The patients
who refused CDS were frequently older, African American, widowed or divorced, and had advanced-stage tumors. In a logistic
regression analysis, older age, African American, and being divorced or widowed were independently associated with refusal of
CDS. After adjusting for other patient and tumor characteristics, the patients who refused CDS had a 2.5-fold (95% conﬁdence
interval, 2.339–3.189) higher risk of dying from HCC in comparison with patients who had CDS. Conclusions: The high rate of
refusal maycontribute in part to the disparity in utilization of CDS. Of greatest concern is that the patients who declined CDS had
an impaired survival. This informationmight be helpful for patients to make a better-informed decision.
1.Introduction
Hepatocellular carcinoma (HCC) is the most frequent
primary liver cancer. The annual number of new cases
worldwide is approximately 550,000,representing more than
5% of human cancers and the third leading cause of cancer-
related deaths [1, 2].
The goal of cancer-directed surgery (CDS) is to com-
pletely remove localized tumors or reduce the size of
large tumors. CDS includes the curative surgeries (such as
hepatectomyandtransplantation)andlocalregionaltherapy,
which employ modern surgical tools (including laser, high-
frequencyelectrical currents, radiation, and liquidnitrogen),
sometimes in conjunction with alcohol or chemotherapy
agents. Resection and transplantation oﬀer the best chance
of long-term, disease-free survival and overall survival for
patientswithHCC.Inalargeseries ofpatientsfromspecialty
institutions, the median survival of those who underwent
resection of HCC lesions has ranged from 30 to 70 months
[2–6]. Local regional therapy can provide alternatives for
patients who are not candidate for resection or trans-
plantation. Recently, chemoembolation has demonstrated
survivalbeneﬁts[7–11].The5-yearsurvivalratesforpatients
who underwent surgery, transhepatic arterial embolization
(TAE), or supportive treatment were 43.6%, 25.6%, and
3.7%, respectively [5].
Signiﬁcant advances in preoperative evaluation, surgical
techniques, and postoperative care have reduced perioper-
ative morbidity and mortality associated with liver surgery
[11–18]. However, not all patients agree to the CDS rec-
ommended by their surgeon, even when it is potentially
lifesaving or life prolonging. Patients who face the option
of surgical interventions must examine/weigh the potential
tradeoﬀs between beneﬁts and burdens. For some patients2 International Journal of Surgical Oncology
surgery remains an invasive, risky intervention; thus, they
may choose not to be operated on. Although there has been
a great deal of investigation into decision making by patients
with cancer, remarkably, there is virtually no research on the
frequency of HCC patients refusing CDS and the factors that
inﬂuence their decisions. Understanding the factors under-
lying refusal can direct/guide strategies to improve patient
satisfaction, surgical utilization, and outcome of cancer care.
The aim of this population-based study was to assess the
frequency of refusal of CDS, identify the characteristics of
patients who decide to refuse the recommended CDS for
HCC, and estimate the impact of this decision on disease-
speciﬁc survival.
2.PatientsandMethods
2.1. Data Source and Cohort. The study cohort was com-
posed of patients registered to the National Cancer Insti-
tute Surveillance, Epidemiology, and End Results (SEER)
Program from 1985 to 2004. The SEER program collects
uniformly reported data from 17 population-based cancer
registries covering approximately 26.2% of the US popula-
tion [19].
All adult patients with a microscopically conﬁrmed
diagnosis of HCC between 1985 and 2004 were identiﬁed
using International Classiﬁcation of Diseases for Oncology,
third edition, histology codes 8170 (HCC) in combination
with site code C22.0 (liver). We excluded the cases that were
diagnosed atautopsy oron the basisofdeathcertiﬁcates only
as well as patients with multiple primaries.
Demographic information recorded for each patient
included age, sex, race/ethnicity, marital status, and year
of diagnosis. These data were also included in multivariate
analysesascovariates.Cancer-speciﬁcdataevaluatedforeach
patient included stage at presentation and histology grade.
The tumor stage was evaluated using the SEER historic
staging system (localized, regional, and distant).
Cancer-directed surgery (CDS) was deﬁned in the SEER
database as any treatment that is given to modify, control,
remove, or destroy primary or metastatic cancer tissue.
These treatments included surgical resection (hepatectomy),
transplantation, andlocalregionaltherapy(suchas radiation
frequency ablation, chemoembolization, and embolization)
based on values for site-speciﬁc surgery and codes for the
surgery of the primary site within the database [19].
The SEER database collected data from the clinical
ﬁles of all HCC patients who were recommended or not
recommended to undergo CDS; we diﬀerentiated between
t h o s ew h or e f u s e ds u r g e r ya n dt h o s ew h od i dn o th a v e
surgery for other reasons. Whether patients underwent CDS
(i.e., surgery intended for cure) was noted, the reason for
not undergoing CDS was classiﬁed as “not recommended”,
“contraindicated”, “refused”, or “unknown”. SEER collects
this variable directly from the patient’s medical record. “Not
recommended”iscodedifthephysicianbelievedthatsurgery
wasnotthebesttreatmentoption,“contraindicated”iscoded
if a medical contraindication exists, and “refused” is coded if
the patient refused surgery [19].
2.2. Statistical Analysis. Cancer-speciﬁc survival was studied
by the actuarial method. Kaplan and Meier estimates of
survival [20] and Cox proportional hazards model [21]w e r e
used to evaluate the impact that potential prognostic vari-
ables have on survival. Statistical analyses were performed
with SPSS software (SPSS 10 version, Chicago, IL).
This study was approved by the University of Nebraska
Medical Center Institutional Review Boards.
3.Results
3.1. Patient and Tumor Characteristics and Frequency of
Cancer-Directed Surgery Refusal. A total of 8806 adult
patients with localized HCC were identiﬁed in the SEER
Registry between January 1985 and December 2004; the
mean age of the cohort was 64 ± 13 years old (median age
is 64 years, with a range of 18 to 104 years). The majority
ofpatientswere white, accountingfor 5532patients(63.3%).
There were 947 African American patients (10.8%), and the
other ethnic groups comprised 2266 patients (25.9%).
Oftheentirecohort,4373(49.7%)wererecommendedto
undergo CDS, while 4372 (49.6%) patients were determined
not to be surgical candidates. No information was provided
for the rest of the 61 (0.7%) patients. Table 1 provides
detailed information about the demographics, tumor char-
acteristics, and treatments of the 4373 CDS candidates and
4372noncandidates. Thesurgicalcandidateswereonaverage
three years older(62±13 years) than the nonCDScandidates
(65 ± 13 years) and more likely to be married.
Among the 4373 surgical candidates, 3016 (68.9%)
patients eventually had CDS performed; 142 (3.2%) patients
declined the recommended CDS; 1125 (25.7%) patients did
not undergo CDS for unknown reasons; 79 (1.8%) patients
had no information regarding whether the recommended
CDS was performed; and the remaining 11 (0.2%) patients
died prior to their planned CDS.
3.2. Factors Associated with Surgical Candidate Recommenda-
tions/Selection. In a logistic regression analysis, age, marital
status, tumor grade, size, and later year of diagnosis were
found signiﬁcantly correlated with being recommended to
have CDS. Younger age and being married were independent
predictors of selection for CDS. There was no racial diﬀer-
ence between CDS candidates and noncandidates (Table 3).
3.3. Factors Associated with Refusal of Cancer-Directed
Surgery. Table 2 presents the demographic and clinical char-
acteristics of the patients who refused CDS (N = 142)
or accepted and underwent CDS (N = 3016) and those
patients did not undergo CDS for unknown reasons (N =
1125). The patients who refused surgery were on average
eight years older (68 ± 13 years) than the patients who
acceptedCDS(60±12years).Theywerealsomorefrequently
nonCaucasian. The tendency to refuse CDS was signiﬁcantly
higher in those divorced and widowed. The demographic
and clinical characteristics of the patients who, refused CDS
and those patients did not undergo CDS for unknown
reasons are very similar.International Journal of Surgical Oncology 3
Table 1: Demographic and clinicalcharacteristics of patients with localized HCC. CDS: cancer-directed surgery.
Group CDS candidates NonCDS candidates P
N = 4373 N = 4372
Age (mean ± SD) 65 ±13 62 ±13 <.001
Age group <.001
<60 1924 (44.0%) 1466 (33.5%)
≥60 2449 (56.0%) 2906 (66.5%)
Gender .59
Male 3137 (71.7%) 3174 (72.6%)
Female 1236 (28.3%) 1198 (27.4%)
Race .74
White 2786 (63.7%) 2746 (62.8%)
Black 454 (10.4%) 493 (11.3%)
Asian 1050 (24.0%) 1072 (24.5%)
American Indian 62 (1.4%) 43 (1.0%)
Unknown 21 (0.5%) 18 (0.4%)
Marital status .001
Married 2715 (62.1%) 2400 (54.9%)
Divorced 406 (9.3%) 456 (10.4%)
Separated 44 (1.0%) 54 (1.2%)
Single 581(9.8%) 678 (15.5%)
Windowed 473 (10.8%) 653 (14.9%)
Unknown 154 (3.5%) 131 (3.0%)
Grade <.001
Well diﬀerentiated 1043 (23.9%) 617 (14.1%)
Moderately diﬀerentiated 1025 (23.4%) 428 (9.8%)
Poorly diﬀerentiated 378 (8.6%) 323 (7.4%)
Undiﬀerentiated 50 (1.1%) 37 (0.8%)
Unknown 1877 (42.9%) 2967 (39.1%)
Tumor size .01
<5cm 206 (4.7%) 236 (5.4%)
≥5cm 383 (8.8%) 315 (7.2%)
Unknown 3784 (86.5%) 3821 (87.4%)
Year of diagnosis .46
1985–1994 663 (15.2%) 638 (14.6%)
1995–2004 3710 (84.8%) 3734 (85.4%)
Table 4 presents the results of a multivariable analysis
of factors associated with refusal of CDS. The results of
the analysis showed that older age, African American, being
divorced, or being widowed and larger tumor size were
independently associated with refusal of CDS.
3.4.RefusalofCancer-Directed Surgery andMortality. Table 5
presentstheresultsofmultivariatesurvivalanalyses usingthe
Cox proportional hazards model. Refusal of CDS was iden-
tiﬁed as an independent factor for cancer-speciﬁc mortality.
The risk of dying of HCC was increased by 2.5 fold (hazard
ratio, 2.5; 95% conﬁdence interval, 2.046–3.013) among
patients who refused CDS in comparison with those who
accepted CDS. Older age, male gender, African American,
being widowed, and having a higher-grade tumor and an
earlier diagnosis year were also independently associated
with a higher cancer-speciﬁc mortality.
Figure 1 shows the cancer-speciﬁc survival curves of
patients refusing and patients accepting CDS. The patients
with localized HCC who refused CDS had a survival similar
to those who were considered nonsurgical candidates.
4.Discussion
The use of CDS as a cornerstone treatment of early-stage
HCC has evolved over the last 20 years; signiﬁcant advances
in preoperative evaluation, surgical techniques, and postop-
erative care have reduced the perioperative morbidity and
mortality associated with liver surgery [11–15]. Mortality
after hepatectomy has dropped from approximately 25% in
the 1960s to less than 3% today and investigators from high-
volume centers report 0% mortality [18]. Hepatectomy and
liver transplantation remain the only potentially curative
therapy for localized liver cancer [5, 6]. Furthermore,4 International Journal of Surgical Oncology
Table 2: Comparison of patients with localized HCC who had, with those who, refused CDS, and those CDS were not performed due to
unknown reason. CDS: cancer-directed surgery.
Refused CDS Not performed
N(%) N(%) N(%)
Age (mean ± SD) 68 ± 13 60 ± 12 66 ±13
Age group
<60 35 (24.6) 1494 (49.5) 354 (31.5)
≥60 107 (75.5) 1522 (50.5) 771 (68.5)
Gender
Male 99 (69.7) 2139 (70.9) 827 (73.5)
Female 43 (30.3) 877 (29.1) 298 (26.5)
Race
White 79 (55.6) 1875 (62.2) 778 (69.2)
Black 19 (13.4) 267 (8.9) 157 (14.0)
Asian 40 (28.2) 826 (27.4) 159 (14.1)
American Indian 4 (2.8) 33 (1.1) 25 (2.2)
Unknown 0 (0.0) 15 (0.5) 6 (0.5)
Marital status
Married 72 (50.7) 1976 (65.5) 610 (54.2)
Divorced 18 (12.8) 258 (8.6) 121 (10.8)
Separated 0 (0.0) 37 (1.2) 7 (0.6)
Single 15 (10.6) 395 (13.1) 156 (13.9)
Windowed 28 (19.7) 272 (9.0) 168 (14.9)
Unknown 9 (6.3) 78 (2.6) 63 (5.6)
Grade
Well diﬀerentiated 19 (13.4) 801 (26.6) 205 (18.2)
Moderately diﬀerentiated 17 (12.0) 875 (29.0) 125 (11.1)
Poorly diﬀerentiated 9 (6.3) 282 (9.4) 78 (6.9)
Undiﬀerentiated 0 (0.0) 39 (1.3) 10 (0.9)
Unknown 97 (68.3) 1019 (33.8) 707 (62.9)
Tumor size
<5cm 5 (3.5) 364 (12.1) 11 (1.0)
≥5cm 8 (5.6) 171 (5.7) 23 (2.0)
Unknown 129 (90.8) 2481 (82.3) 1091 (97.0)
Year of diagnosis
1985–1994 23 (16.2%) 345 (11.4) 290 (25.8)
1995–2004 119 (83.8) 2671 (88.6) 835 (74.2)
several multi-institutional randomized clinical trials have
demonstrated the safety and eﬃcacyoflocal regional surgery
(radiofrequency and chemoembolization) in the manage-
ment of HCC [6–10].
This study is the ﬁrst to quantify how often CDS is
refused and the ﬁrst to examine the common features
of patients with HCC who refuse CDS and the impact
that their refusal has on cancer-speciﬁc survival. We found
3.2% of the surgical candidates refused a cancer-directed
surgical intervention. This result is compatiblewith previous
ﬁndings [20, 22]. Our results clearly demonstrate that
the risk of dying from HCC is more than doubled for
patients who refuse CDS compared to those who undergo
the recommended CDS, regardless of demographic factors,
tumor grade, and stage.
Inourstudy,theolder,unmarriedpatientswerelesslikely
to be recommended CDS and more likely to refuse CDS
if it was oﬀered than their younger, married counterparts.
Although race was not associated with selection for CDS,
African American patients were more likely to refuse a
surgical intervention than their Caucasian counterparts.
Physicians should be aware that these patients are at an
increased risk to refuse surgery. For this population in par-
ticular, surgeons should strive for eﬀective communication
with thepatient and emphasize the important role ofsurgery
in managing HCC.
Elderly patients tend to receive less optimal therapy
than younger patients [23]; the reasons for this observa-
tion remain elusive. Whether the reason is the physician’s
perceived high operative risk, the lack of long-term beneﬁtsInternational Journal of Surgical Oncology 5
Table 3: Logisticregression analysis of factors associated with recommendation of cancer-directed surgery in patients with localized HCC.
Characteristics Group OR 95% Cl P-value
Age <60 1.00
≥60 0.606 0.551–0.667 <.001
Gender Female 1.00
Male 0.816 0.735–0.906 <.001
Ethnicity
White 1.00
Black 0.920 0.794–1.066 .268
Others 0.962 0.868–1.067 .465
Marital status
Married 1.00
Widowed 0.696 0.602–0.805 <.001
Divorced/separated 0.731 0.631–0.847 <.001
Singled 0.705 0.616–0.806 <.001
Other 1.016 0.791–1.304 .903
Grade
Low grade 1.00
High grade 0.609 0.518–0.716 <.001
Unknown 0.319 0.290–0.351 <.001
Tumor size
<5cm 1.00
≥5cm 0.398 0.310–0.510 <.001
Unknown 0.652 0.546–0.779 <.001
Year of diagnosis 1985–1994 1.00
1995–2004 0.841 0.742–0.954 .007
OR = odds ratio; CI = conﬁdence interval.
P<. 0001
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Figure 1: Cancer-speciﬁc survival in patients with HCC who
refused or underwent cancer-directed surgery. Cancer-speciﬁc
survival curve: A, CDS; B, CDS refused; C, CDS recommended but
not performed; D, noncandidates for CDS.
in elderly patients, or the physician’s greater investment
in convincing younger patients of the beneﬁt of CDS, the
topic needs further investigation [23, 24]. Our ﬁnding of a
higher rate of refusal in the elderly likely serves as another
explanation for the underuse of CDS in this population.
The impact of age on operative risk is controversial.
In a study of elderly patients with HCC, the survival
diﬀerence by age disappeared when patients were compared
within each treatment group, suggesting a close link between
undertreatment and shorter survival [25]; for the patients
with good liver function and good performance status,
aggressive treatment of HCC improved the survival rate,
even in the extremely elderly patients [26, 27]. Hepatic
resection and transcatheter arterial chemoembolization for
HCC in elderly patients (>70 years) were well tolerated and
l e dt oa ni m p r o v e ds u r v i v a lr a t e[ 7]. Age alone should not
be considered a contraindication to liver surgery [2, 5, 6].
Because performance status and physiological age are more
important than chronologicalage, elderlypatientswith HCC
should be fully evaluated to select all patients who would
potentially beneﬁt from aggressive surgical strategies.
Previous studies have shown that African Americans and
Asians are also signiﬁcantly less likely to receive a transplant
[28]. Blacks were found 24–27% less likely to receive surgical
therapy than white individuals. The racial disparities in uti-
lizing surgical treatment and in survival were most striking
betweenblackandwhitepatientswithlocalizedHCC[29].In
addition to their potentially reduced access to medical care,
the high rate of refusal in black patients may explain, at least
partially, the underuse of CDSinthis population.The higher
refusal rate may be attributable to cultural reasons, personal
beliefs, diﬀerent perceptions of surgery [30], and distrust of
health care systems [8]. We found no signiﬁcant diﬀerencein
the selection of CDS candidates between African American
and white patients; however, once recommended to have
surgery, African Americans are more likely to refuse CDS.
Few studies address the natural history of HCC, that is,
the outcome of HCC without therapy [31, 32]. In our study,
we found that refusal of CDS has a signiﬁcant impact on the6 International Journal of Surgical Oncology
Table 4: Logisticregression analysis of factors associated with refusal of cancer-directed surgery in patients with localized HCC.
Characteristics Group OR 95% Cl P-value
Age <60 1.00
≥60 2.901 1.921–4.383 <.001
Gender Female 1.00
Male 1.445 0.961–2.173 .077
Ethnicity
White 1.00
Black 1.836 1.065–3.168 .029
Others 1.172 0.791–1.735 .429
Marital status
Married 1.00
Widowed 2.395 1.438–3.990 .001
Divorced/separated 1.947 1.110–3.417 .020
Singled 1.199 0.664–2.165 .548
Other 3.128 1.466–6.677 .003
Grade
Low grade 1.00
High grade 1.552 0.733–3.284 .250
Unknown 4.432 2.983–6.586 <.001
Tumor size
<5cm 1.00 .017
≥5cm 4.036 1.277–12.755
Unknown 3.595 1.443–8.957
Year of diagnosis 1985–1994 1.00
1995–2004 0.859 0.530–1.393 .538
OR = odds ratio; CI = conﬁdence interval.
Table 5: Cox proportional hazards model of factors associated with cancer-speciﬁc mortality in patients with localized HCC.
Characteristics Group HR 95% Cl P-value
Age <60 1.00
≥60 1.223 1.156–1.295 <.001
Gender Female 1.00
Male 1.132 1.067–1.202 <.001
Ethnicity
White 1.00
Black 1.145 1.055–1.242 .001
Others 0.828 0.780–0.880 <.001
Marital status
Married 1.00
Widowed 1.220 1.128–1.319 <.001
Divorced/separated 1.027 0.943–1.118 .540
Singled 1.054 0.976–1.139 .181
Others 1.131 0.983–1.300 .084
Grade
Low grade 1.00
High grade 1.608 1.465–1.766 <.001
Unknown 1.262 1.190–1.338 <.001
Tumor size
<5cm 1.00
≥5cm 1.978 1.556–2.515 <.001
Unknown 1.942 1.593–2.366 <.001
Diagnosis year 1989–2004 1.00
1973–1988 0.741 0.695–0.791 <.001
CDS
Performed 1.00
Refused 2.444 2.014–2.966 <.001
Nonsurgical candidate 3.215 3.003–3.441 <.001
HR = hazard ratio; CI = conﬁdence interval; CDS: cancer-directed surgery.International Journal of Surgical Oncology 7
cancer-speciﬁc survival of patients with HCC. The survival
of these patients was similar to the nonsurgical candidates.
Since there was no eﬀective chemotherapy for HCC during
the study period, because CDS oﬀers the best chance of
survival for most HCC patients [1, 2], it should be evaluated
carefully and oﬀered to patients who may potentially beneﬁt
from it.
Treatment refusal may be a marker for insuﬃcient
patient-centered decision making, as patients may refuse
treatments that they perceive as inadequate in meeting their
treatment goals. Our study suggests that surgeons may be
recommending treatments that pose unacceptable burdens
to some patients or that fail to meet the patients’ goals;
we found old age is one of the greatest risk factors of
refusing CDS. Given the rapidly aging population, further
studies should focus on identifying speciﬁc reasons why
these patients refuse CDS. The new breakthrough of therapy
with signal transduction inhibitors, such as soraﬁnib, can
provide an alternative for those patients who refuse CDS
[31];however,patientsneedtobeawarethatthisnewtherapy
is clearly palliative.
Our study has some limitations. First, decision making
regarding surgery is a complex process and involves both
care-provider and patient factors. Although we were able
to create a cohort with a full range of demographic and
clinical variables, we were unable to assess the patient’s
performance status, comorbidities, and other factors such as
characteristics of the surgeon that might inﬂuence receipt
or refusal of CDS. This study was also limited by the
retrospective and nonrandomized nature of any registry-
based study [33]; even after adjusting for all available
variables linked to patient refusal or prognosis, we cannot
ruleoutaselectionbiasrelatedtounrecordedfactors.Finally,
the clinical information available from a registry is not as
detailed as that from chart review. However, the use of
speciﬁc survival rather than overall survival in our study has
modiﬁed the limitation to some degree.
Despite its limitations, our study adds to the knowledge
of disparities cancer treatment related to age, race and
marital status. First, the sample size was large enough for
us to assess the patterns of care in a diverse population and
to examine a number of potentially confounding variables.
Second, our study may partially explain why the use of
CDS varies by age and race. Further research should focus
on the physician-patient encounter as a potential source of
these disparities [31], allowing a better understanding of
theunderlyingreasonforrefusal.Enhancingcommunication
may be one of the simplest approaches to reduce the
disparities in surgical treatment in cancer patients. Both
patients and surgeons need to be educated in optimal HCC
management.
In summary, using a national population-based data
sample, we found 3.2% of surgical candidates refused
CDS for HCC. We compared the characteristics of these
patients and investigated the impact of refusal on mortality.
The higher rate of refusal may contribute in part to the
underutilization of CDS in certain populations. To make a
well-informed decision, patients should be informed of both
the beneﬁcial and adverse eﬀects of the treatment options.
The patients have full rights in their decision of cancer
treatment. However, some patients who refuse CDS may
miss out on the only prospect of prolonging their lives or
even on the opportunity of being cured. The ﬁndings of this
study may be helpful for those patients who are facing this
therapeutic decision.
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